CAP’s Pharmaceutical Industry Report analyzes the executive compensation practices of 19 large pharmaceutical and biotechnology companies. As of December 31, 2015, the companies in our sample had median revenues of $23B and median market cap of $113B. In addition to reviewing the entire sample, we assessed U.S. companies (n=12) and non-U.S. companies (n=7) separately to discern trends in pay, performance and practices.

2015 Financial Results: Pharmaceutical companies experienced strong stock price appreciation and revenue growth relative to the broader market.

Click here to download the full report